Abstract:The number of successful drug development projects has been stagnant for decades despite major breakthroughs in chemistry, molecular biology, and genetics. Unreliable target identification and poor translatability of preclinical models have been identified as major causes of failure. To improve predictions of clinical efficacy and safety, interest has shifted to three-dimensional culture methods in which human cells can retain many physiologically and functionally relevant phenotypes for extended periods of time. Here, we review the state of the art of available organotypic culture techniques and critically review emerging models of human tissues with key importance for pharmacokinetics, pharmacodynamics, and toxicity. In addition, developments in bioprinting and microfluidic multiorgan cultures to emulate systemic drug disposition are summarized. We close by highlighting important trends regarding the fabrication of organotypic culture platforms and the choice of platform material to limit drug absorption and polymer leaching while supporting the phenotypic maintenance of cultured cells and allowing for scalable device fabrication. We conclude that organotypic and microphysiological human tissue models constitute promising systems to promote drug discovery and development by facilitating drug target identification and improving the preclinical evaluation of drug toxicity and pharmacokinetics. There is, however, a critical need for further validation, benchmarking, and consolidation efforts ideally conducted in intersectoral multicenter settings to accelerate acceptance of these novel models as reliable tools for translational pharmacology and toxicology. SIGNIFICANCE STATEMENT: Organotypic and microphysiological culture of human cells has emerged as a promising tool for preclinical drug discovery and development that might be able to narrow the translation gap. This review discusses recent technological and methodological advancements and the use of these systems for hit discovery and the evaluation of toxicity, clearance, and absorption of lead compounds.

Recent Advances in Organotypic Tissue Slice Cultures for Anticancer Drug Development

Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discovery

The application of pancreatic cancer organoids for novel drug discovery

Organoids: approaches and utility in cancer research

Organoids: opportunities and challenges of cancer therapy

Advances and Applications of Cancer Organoids in Drug Screening and Personalized Medicine

Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy

High-throughput solutions in tumor organoids: From culture to drug screening

Progress in the Application of Organoids to Breast Cancer Research

Patient-derived Organoids (pdos) and PDO-derived Xenografts (pdoxs): New Opportunities in Establishing Faithful Pre-Clinical Cancer Models

Organoid models of the tumor microenvironment and their applications

Perfused Three-dimensional Organotypic Culture of Human Cancer Cells for Therapeutic Evaluation

Advances in Tumor Organoids for the Evaluation of Drugs: A Bibliographic Review

Patient-Derived Tumor Organoids: New Progress and Opportunities to Facilitate Precision Cancer Immunotherapy

Unlocking the potential of organoids in cancer treatment and translational research: An application of cytologic techniques

Advancing cancer research through organoid technology

Organoid technology and applications in cancer research

A new approach to assess drug sensitivity in cells for novel drug discovery

Tumor organoids: From inception to future in cancer research

Organotypic and Microphysiological Human Tissue Models for Drug Discovery and Development-Current State-of-the-Art and Future Perspectives

Progress and Perspective of Organoid Technology in Cancer-Related Translational Medicine.